Megan E Miller1, Shirin Muhsen1, Cristina Olcese1, Sujata Patil2, Monica Morrow1,3, Kimberly J Van Zee4,5. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Weill Medical College at Cornell University, 300 East 66th Street, New York, NY, USA. 4. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vanzeek@mskcc.org. 5. Weill Medical College at Cornell University, 300 East 66th Street, New York, NY, USA. vanzeek@mskcc.org.
Abstract
BACKGROUND: Women with ductal carcinoma in situ (DCIS) are increasingly choosing bilateral mastectomy. We sought to quantify rates of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) for DCIS, and to compare risk factors for CBC and IBTR. METHODS: From 1978 to 2011, DCIS patients undergoing BCS with a contralateral breast at risk were identified from a prospectively maintained database. The association of clinicopathologic and treatment factors with CBC and IBTR were evaluated using Kaplan-Meier analysis, multivariable Cox regression, and competing risk regression (CRR). RESULTS: Of 2759 patients identified, 151 developed CBC and 344 developed IBTR. Five- and 10-year Kaplan-Meier CBC rates were 3.2 and 6.4%. Overall, 10-year IBTR rates were 2.5-fold higher than CBC rates, and, without radiation, 4-fold higher. On CRR, 5- and 10-year rates were 2.9 and 5.8% for CBC, and 7.8 and 14.5% for IBTR. CBC risk and invasive CBC risk were not significantly associated with age, family history, presentation, nuclear grade, year of surgery, or radiation. By multivariable Cox regression, endocrine therapy was associated with lower CBC risk (hazard ratio 0.57, p = 0.03). Ten-year risk of subsequent CBC in the subset of patients who developed IBTR was similar to the cohort as a whole (8.1 vs. 6.4%). CONCLUSIONS: CBC rates were low across all groups, including those who experienced IBTR. CBC was not associated with factors that increase IBTR risk. While factors associated with IBTR risk are important in decision making regarding management of the index DCIS, they are not an indication for contralateral prophylactic mastectomy.
BACKGROUND:Women with ductal carcinoma in situ (DCIS) are increasingly choosing bilateral mastectomy. We sought to quantify rates of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) for DCIS, and to compare risk factors for CBC and IBTR. METHODS: From 1978 to 2011, DCIS patients undergoing BCS with a contralateral breast at risk were identified from a prospectively maintained database. The association of clinicopathologic and treatment factors with CBC and IBTR were evaluated using Kaplan-Meier analysis, multivariable Cox regression, and competing risk regression (CRR). RESULTS: Of 2759 patients identified, 151 developed CBC and 344 developed IBTR. Five- and 10-year Kaplan-Meier CBC rates were 3.2 and 6.4%. Overall, 10-year IBTR rates were 2.5-fold higher than CBC rates, and, without radiation, 4-fold higher. On CRR, 5- and 10-year rates were 2.9 and 5.8% for CBC, and 7.8 and 14.5% for IBTR. CBC risk and invasive CBC risk were not significantly associated with age, family history, presentation, nuclear grade, year of surgery, or radiation. By multivariable Cox regression, endocrine therapy was associated with lower CBC risk (hazard ratio 0.57, p = 0.03). Ten-year risk of subsequent CBC in the subset of patients who developed IBTR was similar to the cohort as a whole (8.1 vs. 6.4%). CONCLUSIONS: CBC rates were low across all groups, including those who experienced IBTR. CBC was not associated with factors that increase IBTR risk. While factors associated with IBTR risk are important in decision making regarding management of the index DCIS, they are not an indication for contralateral prophylactic mastectomy.
Authors: K J Van Zee; L Liberman; B Samli; K N Tran; B McCormick; J A Petrek; P P Rosen; P I Borgen Journal: Cancer Date: 1999-11-01 Impact factor: 6.860
Authors: Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: Andrea Altschuler; Larissa Nekhlyudov; Sharon J Rolnick; Sarah M Greene; Joann G Elmore; Carmen N West; Lisa J Herrinton; Emily L Harris; Suzanne W Fletcher; Karen M Emmons; Ann M Geiger Journal: Breast J Date: 2008 Jan-Feb Impact factor: 2.431
Authors: Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George Journal: Lancet Oncol Date: 2010-12-07 Impact factor: 41.316
Authors: Tawakalitu O Oseni; Barbara L Smith; Constance D Lehman; Charmi A Vijapura; Niveditha Pinnamaneni; Manisha Bahl Journal: Ann Surg Oncol Date: 2020-05-16 Impact factor: 5.344
Authors: Daniele Giardiello; Iris Kramer; Maartje J Hooning; Michael Hauptmann; Esther H Lips; Elinor Sawyer; Alastair M Thompson; Linda de Munck; Sabine Siesling; Jelle Wesseling; Ewout W Steyerberg; Marjanka K Schmidt Journal: NPJ Breast Cancer Date: 2020-11-03